[Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].
Identifieur interne : 000071 ( PubMed/Corpus ); précédent : 000070; suivant : 000072[Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].
Auteurs : J. Liu ; J H Chen ; Y Q Wang ; G M Nong ; Y J Zheng ; C L HaoSource :
- Zhonghua er ke za zhi = Chinese journal of pediatrics [ 0578-1310 ] ; 2019.
English descriptors
- KwdEn :
- Child, Glucocorticoids (therapeutic use), Humans, Infant, Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (genetics), Mutation, Protein C (genetics), Pulmonary Surfactant-Associated Protein C (genetics), Pulmonary Surfactants, Retrospective Studies, Surface-Active Agents, Treatment Outcome.
- MESH :
- chemical , genetics : Protein C, Pulmonary Surfactant-Associated Protein C.
- chemical , therapeutic use : Glucocorticoids.
- drug therapy : Lung Diseases, Interstitial.
- genetics : Lung Diseases, Interstitial.
- Child, Humans, Infant, Mutation, Pulmonary Surfactants, Retrospective Studies, Surface-Active Agents, Treatment Outcome.
Abstract
Objective: To investigate the clinical features and outcomes of pulmonary surfactant protein C gene (SFTPC) 218 site mutation in children with pulmonary interstitial disease. Methods: In this retrospective study, the clinical data, outcomes and influencing factors of 7 cases of SFTPC gene 218 site mutations in infants with interstitial lung disease in three hospitals from January 2013 to December 2016 were analyzed. Results: Seven cases were full-term children, 4 cases had the onset within 3 months after birth, 2 cases after 1 year old, 1 case within 3 months to 1 year, clinical manifestations of these cases were cough, shortness of breath, dyspnea, and limited growth and development, could not maintain life without additional oxygen supplementation, blood gas analysis showed hypoxemia, 4 cases had clubbing. Chest CT showed diffuse ground glass-like change in both lungs. Three cases were positive for cytomegalovirus (CMV)-IgM or CMV-DNA. The mutations in 7 cases were exon 3, 5 of which were SFTPC gene c.218T>C, p.lle73Thr (heterozygous mutation), and 2 cases were SFTPC gene c.218T>A, p.lle73Asn (homozygous mutation), 1 case combined with ABCA3 gene mutations. Four patients were treated with prednisone alone, one with prednisone plus hydroxychloroquine, and two with symptomatic treatment. Three patients died, 3 patients improved, and 1 patient was lost to follow-up. Conclusions: The severity and prognosis of the children with SP-C 218 site mutation may be affected by many factors. Some children who received glucocorticoid alone do not have a good response.
DOI: 10.3760/cma.j.issn.0578-1310.2019.01.007
PubMed: 30630227
Links to Exploration step
pubmed:30630227Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].</title>
<author><name sortKey="Liu, J" sort="Liu, J" uniqKey="Liu J" first="J" last="Liu">J. Liu</name>
<affiliation><nlm:affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, J H" sort="Chen, J H" uniqKey="Chen J" first="J H" last="Chen">J H Chen</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Y Q" sort="Wang, Y Q" uniqKey="Wang Y" first="Y Q" last="Wang">Y Q Wang</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nong, G M" sort="Nong, G M" uniqKey="Nong G" first="G M" last="Nong">G M Nong</name>
<affiliation><nlm:affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zheng, Y J" sort="Zheng, Y J" uniqKey="Zheng Y" first="Y J" last="Zheng">Y J Zheng</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hao, C L" sort="Hao, C L" uniqKey="Hao C" first="C L" last="Hao">C L Hao</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30630227</idno>
<idno type="pmid">30630227</idno>
<idno type="doi">10.3760/cma.j.issn.0578-1310.2019.01.007</idno>
<idno type="wicri:Area/PubMed/Corpus">000071</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000071</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].</title>
<author><name sortKey="Liu, J" sort="Liu, J" uniqKey="Liu J" first="J" last="Liu">J. Liu</name>
<affiliation><nlm:affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, J H" sort="Chen, J H" uniqKey="Chen J" first="J H" last="Chen">J H Chen</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Y Q" sort="Wang, Y Q" uniqKey="Wang Y" first="Y Q" last="Wang">Y Q Wang</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nong, G M" sort="Nong, G M" uniqKey="Nong G" first="G M" last="Nong">G M Nong</name>
<affiliation><nlm:affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zheng, Y J" sort="Zheng, Y J" uniqKey="Zheng Y" first="Y J" last="Zheng">Y J Zheng</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hao, C L" sort="Hao, C L" uniqKey="Hao C" first="C L" last="Hao">C L Hao</name>
<affiliation><nlm:affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Zhonghua er ke za zhi = Chinese journal of pediatrics</title>
<idno type="ISSN">0578-1310</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Humans</term>
<term>Infant</term>
<term>Lung Diseases, Interstitial (drug therapy)</term>
<term>Lung Diseases, Interstitial (genetics)</term>
<term>Mutation</term>
<term>Protein C (genetics)</term>
<term>Pulmonary Surfactant-Associated Protein C (genetics)</term>
<term>Pulmonary Surfactants</term>
<term>Retrospective Studies</term>
<term>Surface-Active Agents</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Protein C</term>
<term>Pulmonary Surfactant-Associated Protein C</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glucocorticoids</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Humans</term>
<term>Infant</term>
<term>Mutation</term>
<term>Pulmonary Surfactants</term>
<term>Retrospective Studies</term>
<term>Surface-Active Agents</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><b>Objective:</b>
To investigate the clinical features and outcomes of pulmonary surfactant protein C gene (SFTPC) 218 site mutation in children with pulmonary interstitial disease. <b>Methods:</b>
In this retrospective study, the clinical data, outcomes and influencing factors of 7 cases of SFTPC gene 218 site mutations in infants with interstitial lung disease in three hospitals from January 2013 to December 2016 were analyzed. <b>Results:</b>
Seven cases were full-term children, 4 cases had the onset within 3 months after birth, 2 cases after 1 year old, 1 case within 3 months to 1 year, clinical manifestations of these cases were cough, shortness of breath, dyspnea, and limited growth and development, could not maintain life without additional oxygen supplementation, blood gas analysis showed hypoxemia, 4 cases had clubbing. Chest CT showed diffuse ground glass-like change in both lungs. Three cases were positive for cytomegalovirus (CMV)-IgM or CMV-DNA. The mutations in 7 cases were exon 3, 5 of which were SFTPC gene c.218T>C, p.lle73Thr (heterozygous mutation), and 2 cases were SFTPC gene c.218T>A, p.lle73Asn (homozygous mutation), 1 case combined with ABCA3 gene mutations. Four patients were treated with prednisone alone, one with prednisone plus hydroxychloroquine, and two with symptomatic treatment. Three patients died, 3 patients improved, and 1 patient was lost to follow-up. <b>Conclusions:</b>
The severity and prognosis of the children with SP-C 218 site mutation may be affected by many factors. Some children who received glucocorticoid alone do not have a good response.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30630227</PMID>
<DateCompleted><Year>2019</Year>
<Month>04</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>04</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0578-1310</ISSN>
<JournalIssue CitedMedium="Print"><Volume>57</Volume>
<Issue>1</Issue>
<PubDate><Year>2019</Year>
<Month>Jan</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Zhonghua er ke za zhi = Chinese journal of pediatrics</Title>
<ISOAbbreviation>Zhonghua Er Ke Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study].</ArticleTitle>
<Pagination><MedlinePgn>21-26</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0578-1310.2019.01.007</ELocationID>
<Abstract><AbstractText><b>Objective:</b>
To investigate the clinical features and outcomes of pulmonary surfactant protein C gene (SFTPC) 218 site mutation in children with pulmonary interstitial disease. <b>Methods:</b>
In this retrospective study, the clinical data, outcomes and influencing factors of 7 cases of SFTPC gene 218 site mutations in infants with interstitial lung disease in three hospitals from January 2013 to December 2016 were analyzed. <b>Results:</b>
Seven cases were full-term children, 4 cases had the onset within 3 months after birth, 2 cases after 1 year old, 1 case within 3 months to 1 year, clinical manifestations of these cases were cough, shortness of breath, dyspnea, and limited growth and development, could not maintain life without additional oxygen supplementation, blood gas analysis showed hypoxemia, 4 cases had clubbing. Chest CT showed diffuse ground glass-like change in both lungs. Three cases were positive for cytomegalovirus (CMV)-IgM or CMV-DNA. The mutations in 7 cases were exon 3, 5 of which were SFTPC gene c.218T>C, p.lle73Thr (heterozygous mutation), and 2 cases were SFTPC gene c.218T>A, p.lle73Asn (homozygous mutation), 1 case combined with ABCA3 gene mutations. Four patients were treated with prednisone alone, one with prednisone plus hydroxychloroquine, and two with symptomatic treatment. Three patients died, 3 patients improved, and 1 patient was lost to follow-up. <b>Conclusions:</b>
The severity and prognosis of the children with SP-C 218 site mutation may be affected by many factors. Some children who received glucocorticoid alone do not have a good response.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Y Q</ForeName>
<Initials>YQ</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nong</LastName>
<ForeName>G M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Y J</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory Disease, Shenzhen Children's Hospital, Shenzhen 518026, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hao</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory Disease, Children's Hospital, Suzhou University, Suzhou 215025, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Zhonghua Er Ke Za Zhi</MedlineTA>
<NlmUniqueID>0417427</NlmUniqueID>
<ISSNLinking>0578-1310</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011486">Protein C</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037721">Pulmonary Surfactant-Associated Protein C</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011663">Pulmonary Surfactants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013501">Surface-Active Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011486" MajorTopicYN="N">Protein C</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037721" MajorTopicYN="Y">Pulmonary Surfactant-Associated Protein C</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011663" MajorTopicYN="N">Pulmonary Surfactants</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013501" MajorTopicYN="N">Surface-Active Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的:</b>
探讨肺表面活性物质蛋白C基因(SFTPC)218位点变异相关性婴幼儿肺间质疾病患儿的临床特点、转归及影响因素。 <b>方法:</b>
回顾性分析广西医科大学第一附属医院儿科、深圳市儿童医院呼吸科及苏州大学附属儿童医院呼吸科2013年1月—2016年12月收治的7例SFTPC基因218位点变异相关性婴幼儿肺间质疾病的临床资料及转归。 <b>结果:</b>
7例患儿均为足月儿,4例3月龄内发病,2例1岁以后发病,1例3月龄至1岁之间发病,临床以咳嗽、气促、呼吸困难等为主要表现,伴生长发育受限,无法脱离鼻导管给氧,血气分析提示低氧血症,4例慢性缺氧、杵状指。胸部CT均表现两肺弥漫性磨玻璃影。3例血巨细胞病毒(CMV)免疫球蛋白M或CMV-DNA阳性。7例患儿变异的部位均在exon3,其中5例患儿为SFTPC基因c.218T>C,p.lle73Thr(杂合变异),2例患儿为SFTPC基因c.218T>A,p.lle73Asn(纯合变异),1例合并ABCA3基因变异。4例患儿单纯应用泼尼松治疗,1例应用泼尼松联合羟氯喹治疗,2例对症治疗。3例死亡,3例好转,1例失访。 <b>结论:</b>
SFTPC基因218位点变异相关的婴幼儿肺间质性疾病的临床表现特异性不强,其严重程度及转归可能受到病毒感染等多因素影响,单独糖皮质激素治疗对部分患儿可能作用有限。.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genes</Keyword>
<Keyword MajorTopicYN="N">Infants</Keyword>
<Keyword MajorTopicYN="N">Interstitial lung disease</Keyword>
<Keyword MajorTopicYN="N">Mutations</Keyword>
<Keyword MajorTopicYN="N">Pulmonary surfactant-related proteins</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30630227</ArticleId>
<ArticleId IdType="doi">10.3760/cma.j.issn.0578-1310.2019.01.007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:30630227 |texte= [Genetic variants in the surfactant protein C gene 218 site are associated with pediatric interstitial lung disease: seven cases study]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:30630227" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |